Protagonist Therapeutics Profit Margin

The latest profit margin for PTGX is 35.85% as of June 2026. That compares with 25.55% in the prior-year period — up 40.3% year over year. That is above the Healthcare sector average of 14.34%. Investors often review this figure alongside Protagonist Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, PTGX's profit margin moved from 25.55% to 35.85% — a 40.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Protagonist Therapeutics's valuation or profitability profile.

Against Healthcare companies, PTGX currently prints 35.85% for profit margin, while the sector average sits near 14.34%. That is roughly 149.9% above the sector mean. Large gaps often invite a closer look at Protagonist Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Protagonist Therapeutics converts resources into returns. At 35.85%, PTGX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 25.55% in the prior-year period — up 40.3% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting PTGX's profit margin (35.85%), review year-over-year change from 25.55%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.